Sector: University & Research Institutions

Latest content

US legislators move to close another “evergreening loophole” for orphan drugs

Recent reforms have made it harder to obtain regulatory exclusivity for follow-on versions of rare disease treatments

24 November 2020

Your guide to covid-19 vaccine stakeholders’ IP strategies

IAM examines the approaches taken by – and the issues facing – the leading companies in the race to find effective coronavirus inoculations

19 November 2020

Samsung taps outside patent lab while spending record amounts on its own R&D

Company is not the only South Korean giant to tap the secondary market as it does more in-house research than ever

18 November 2020

Data is the new frontier in healthcare IP licensing, says award-winning TTO

IAM speaks to the tech transfer office of Oregon Health & Science University about the keys to success in university-industry deal-making

17 November 2020

There has never been a better time to sell or buy drug royalties, says industry veteran

IAM speaks to leading deal-maker David MacNaughtan about his new fund and the growth of this form of life sciences IP monetisation

10 November 2020

Applicants beware: patent oppositions are off the charts in India

Nearly 300% increase over a three-year span indicates greater attention being paid to publications in a jurisdiction where disputes are rising

09 November 2020

Meet the IV veteran creating an IP licensing business in the pharma space

Connie Wan of Seattle Gummy Company talks to IAM about the lessons she learned at the mega-NPE

06 November 2020

Intel’s legal manoeuvrings illustrate varied NPE threat in China

American chipmaker has faced down a big global licensor, a homegrown NPE and a powerful state-linked research organisation

05 November 2020

Amgen suffers another setback in antibody IP war

EPO invalidates PCSK9 patent ahead of crucial CAFC case to be heard next month

04 November 2020

Health insurer’s damages win against AstraZeneca creates new patent risks in The Netherlands

IP owners are liable to be sued by third parties if they assert rights that are subsequently invalidated, rules Dutch court.

27 October 2020

Unlock unlimited access to all IAM content